

HPV Vaccine Available for Routine Use

On December 16, 2016, the Centers for Disease Control and Prevention (CDC) published guidelines in the Morbidity and Mortality Weekly Report (MMWR) recommending a [2-dose, Human Papillomavirus \(HPV\) Gardasil-9 vaccination schedule for use in girls and boys age 9 through 14 years](#). The previous recommendation of a 3-dose schedule remains the same for youth ages 15-26, and those who are immunocompromised.

The newest recommendation from CDC was published in the MMWR on August 16, 2019, which recommends catch up vaccination for everyone through age 26 years. In addition, adults age 27 through 45 years may choose to be vaccinated after having a discussion with their health care provider.

Gardasil-9 is available for protecting persons against HPV:

Gardasil-9 (9-valent HPV9- 6, 11, 16, 18, 31, 33, 45, 52, 58): [Gardasil-9 VIS \(PDF\)](#)

- Licensed by the FDA in 2014 and recommended by ACIP in 2015.
- Recommended for everyone age 9-26 years, including individuals who are immunocompromised and/or HIV-positive.
- Anyone age 27-45 may choose to get the HPV vaccine after talking with their health care provider.
- Protects against oropharyngeal, anal, cervical, vaginal, vulvar, and penile precancer and cancer; and genital warts.
- Contraindication: Persons with a history of immediate hypersensitivity to any vaccine component including yeast.
- Schedule:
 - 2-dose series (0 and 6-12 months) for vaccination initiated at age 9-14 years.
 - 3-dose series (0, 1-2, and 6 months) for vaccination initiated at age 15-45 years, as well as immunocompromised and/or HIV-positive persons age 9-26 years.

ACIP Recommendations for HPV Vaccination

Age When Starting Series	# of Doses	Schedule/Interval
9 to 14 years	2	0, 6-12 months (minimum interval of 5 months between doses)
15 to 45 years	3	0, 1-2, and 6 months
Immunocompromised and/or HIV-positive		

- **Notes:** Gardasil-9 is the only HPV vaccine distributed in the United States. It has been on CDC contracts through the Vaccines For Children (VFC) program since April 2016.
- For information on the supply status of HPV vaccines, visit [Merck's Supply Status](#).
- Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination for immunocompromised persons aged 9 through 26 years with 3 doses of HPV vaccine (0, 1-2, 6 months). Persons who should receive 3 doses are those with primary or secondary immunocompromising conditions that might reduce cell-mediated or humoral immunity, such as B lymphocyte antibody deficiencies, T lymphocyte complete or partial defects, HIV infection, malignant neoplasm, transplantation, autoimmune disease, or immunosuppressive therapy, since immune response to vaccination may be attenuated.*
*The recommendation for a 3 dose schedule for immunocompromised persons does not apply to children with asplenia, asthma, chronic granulomatous disease, chronic liver disease, chronic lung disease, CNS anatomic barrier defects (e.g., cochlear implant), complement deficiency, diabetes, heart disease, persistent complement deficiencies, or sickle cell disease.
- There is no ACIP recommendation for routine additional 9-valent HPV vaccination of persons who previously completed a quadrivalent or bivalent HPV vaccination series.

To request this document in another format, call 1-800-525-0127. Deaf or hard of hearing customers, please call 711 (Washington Relay) or email doh.information@doh.wa.gov. DOH 348-600 July 2024